



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Pemetrexed Fresenius Kabi

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
PSUSA/2330/202402	Periodic Safety Update EU Single assessment - pemetrexed	17/10/2024	19/12/2024	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/2330/202402.
II/0035/G	This was an application for a group of variations. B.II.b.4.z - Change in the batch size (including batch	18/01/2024	19/12/2024	SmPC	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	size ranges) of the finished product - Other variation B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products				
IA/0034	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	24/05/2023	n/a		
IB/0033/G	This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.2.c - Change in test procedure for AS or	16/12/2022	n/a		

	<p>starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p>				
IB/0032	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	26/07/2022	09/08/2023	SmPC and PL	To update sections 4.4 and 4.6 of the SmPC based on the recommended wording provided in the "Report from the CMD(h) meeting held on 20-21 July 2021" concerning duration of contraception following the end of treatment with a genotoxic drug. The PL has been updated accordingly.
IB/0031/G	<p>This was an application for a group of variations.</p> <p>B.II.e.z - Change in container closure system of the Finished Product - Other variation</p>	14/01/2022	n/a		

	<p>B.II.e.z - Change in container closure system of the Finished Product - Other variation</p> <p>B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>				
PSUSA/2330/202102	Periodic Safety Update EU Single assessment - pemetrexed	30/09/2021	n/a		PRAC Recommendation - maintenance
IB/0030/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p>	26/09/2021	n/a		
IA/0029	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	01/06/2021	n/a		

IB/0027	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	31/05/2021	21/06/2022	SmPC	
IAIN/0026/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	26/04/2021	n/a		
R/0023	Renewal of the marketing authorisation.	25/02/2021	21/04/2021	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Pemetrexed Fresenius Kabi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IAIN/0024/G	This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	20/01/2021	21/04/2021	PL	
IB/0022/G	This was an application for a group of variations.	20/11/2020	21/04/2021	SmPC, Annex	

	<p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>			II, Labelling and PL	
IB/0020	B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF	28/10/2020	n/a		
IA/0021	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	19/10/2020	n/a		
IAIN/0019/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	06/07/2020	21/04/2021	Annex II and PL	

IA/0018	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	24/06/2020	n/a		
IB/0017	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	30/05/2020	21/04/2021	SmPC and PL	
X/0009	Annex I 2.(d) Change or addition of a new pharmaceutical form	14/11/2019	11/02/2020	SmPC, Labelling and PL	
IB/0016/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol</p>	18/12/2019	n/a		

IAIN/0015/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	03/10/2019	11/02/2020	Annex II and PL	
IB/0014	C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority	26/04/2019	11/02/2020	SmPC and PL	
IAIN/0013	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	13/03/2019	11/02/2020	Annex II and PL	
IA/0012	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	01/02/2019	n/a		
IA/0011	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -	14/01/2019	n/a		

	Replacement/addition of a site where batch control/testing takes place				
IB/0010	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	20/11/2018	n/a		
IA/0008/G	<p>This was an application for a group of variations.</p> <p>B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>	03/10/2018	n/a		
T/0007	Transfer of Marketing Authorisation	04/06/2018	06/07/2018	SmPC, Labelling and PL	
IB/0006	C.I.z - Changes (Safety/Efficacy) of Human and	13/04/2018	06/07/2018	SmPC and PL	

	Veterinary Medicinal Products - Other variation				
IB/0005	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	18/01/2018	n/a		
IB/0004/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)	14/08/2017	08/05/2018	SmPC	
II/0002	B.I.z - Quality change - Active substance - Other variation	06/07/2017	n/a		
IB/0003	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	22/05/2017	08/05/2018	SmPC and PL	
IB/0001/G	This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a	18/10/2016	n/a		

	<p>starting material/reagent/intermediate for AS -</p> <p>Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p> <p>B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol</p> <p>B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold</p>				
--	--	--	--	--	--